TY - JOUR
T1 - SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
AU - OPTIC Consortium
AU - ISARIC4C Consortium
AU - Dejnirattisai, Wanwisa
AU - Huo, Jiandong
AU - Zhou, Daming
AU - Zahradník, Jiří
AU - Supasa, Piyada
AU - Liu, Chang
AU - Duyvesteyn, Helen M.E.
AU - Ginn, Helen M.
AU - Mentzer, Alexander J.
AU - Tuekprakhon, Aekkachai
AU - Nutalai, Rungtiwa
AU - Wang, Beibei
AU - Dijokaite, Aiste
AU - Khan, Suman
AU - Avinoam, Ori
AU - Bahar, Mohammad
AU - Skelly, Donal
AU - Adele, Sandra
AU - Johnson, Sile Ann
AU - Amini, Ali
AU - Ritter, Thomas G.
AU - Mason, Chris
AU - Dold, Christina
AU - Pan, Daniel
AU - Assadi, Sara
AU - Bellass, Adam
AU - Omo-Dare, Nicola
AU - Koeckerling, David
AU - Flaxman, Amy
AU - Jenkin, Daniel
AU - Aley, Parvinder K.
AU - Voysey, Merryn
AU - Costa Clemens, Sue Ann
AU - Naveca, Felipe Gomes
AU - Nascimento, Valdinete
AU - Nascimento, Fernanda
AU - Fernandes da Costa, Cristiano
AU - Resende, Paola Cristina
AU - Pauvolid-Correa, Alex
AU - Siqueira, Marilda M.
AU - Baillie, Vicky
AU - Serafin, Natali
AU - Kwatra, Gaurav
AU - Da Silva, Kelly
AU - Madhi, Shabir A.
AU - Nunes, Marta C.
AU - Malik, Tariq
AU - Openshaw, Peter J.M.
AU - Baillie, J. Kenneth
AU - Huang, Kuan Ying A.
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/2/3
Y1 - 2022/2/3
N2 - On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
AB - On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
KW - Omicron
KW - RBD
KW - SARS-CoV-2
KW - Spike
KW - immune evasion
KW - receptor interaction
KW - vaccines
KW - variants
UR - http://www.scopus.com/inward/record.url?scp=85123365266&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2021.12.046
DO - 10.1016/j.cell.2021.12.046
M3 - 文章
C2 - 35081335
AN - SCOPUS:85123365266
SN - 0092-8674
VL - 185
SP - 467-484.e15
JO - Cell
JF - Cell
IS - 3
ER -
